Summary of COVID-19 andrographolide studies

1. Zhang et al., Efficacy and safety of Xiyanping injection in the treatment of COVID‐19: A multicenter, prospective, open‐label and randomized controlled trial

130 patient andrographolide late treatment RCT: 92% lower severe cases (p=0.03), 48% improved recovery (p=0.008), and 53% improved viral clearance (p=0.0001).
RCT 130 hospitalized COVID-19 patients in China, showing lower progression and improved recovery with Xiyanping injection (9-dehydro-17-hydro-andrographolide and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate, which are derived from andrographis).
May 2021, Phytotherapy Research, https://onlinelibrary.wiley.com/doi/10.1002/ptr.7141, https://c19p.org/zhang14

2. Siripongboonsitti et al., Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

146 patient andrographolide early treatment RCT: 86% lower need for oxygen therapy (p=0.24), 37% improved recovery (p=0.28), and 5% worse viral clearance (p=0.46).
RCT 146 mild/moderate COVID-19 patients in Thailand, showing no significant difference in clinical outcomes. There were very few serious outcomes.
Aug 2023, Phytomedicine, https://www.sciencedirect.com/science/article/pii/S0944711323003793, https://c19p.org/siripongboonsitti3

3. Prasoppokakorn et al., Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial

82 patient andrographolide early treatment RCT: 37% improved recovery (p=0.005).
Randomized controlled trial of 82 mild COVID-19 outpatients showing significantly greater reduction in cough and lower inflammatory markers at day 7. Symptomatic improvement was significant at day 7 when combining all symptoms reported, but not for other symptoms individually. There was no progression to severe pneumonia in either group.
Feb 2024, OBM Integrative and Complementary Medicine, https://www.lidsen.com/journals/icm/icm-09-01-013, https://c19p.org/prasoppokakorn

4. Wanaratna et al., Efficacy and Safety of Andrographis Paniculata Extract in Patients with Mild COVID-19: A Randomized Controlled Trial

57 patient andrographolide early treatment RCT: 86% lower progression (p=0.11) and 40% improved viral clearance (p=0.11).
RCT 63 mild COVID-19 patients showing lower progression and improved viral clearance with andrographis, without statistical significance.
Jul 2021, Archives of Internal Medicine Research, https://www.fortunejournals.com/articles/efficacy-and-safety-of-andrographis-paniculata-extract-in-patients-with-mild-covid19-a-randomized-controlled-trial.html, https://c19p.org/wanaratna

5. Kanokkangsadal et al., Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial

165 patient andrographolide early treatment RCT: 51% lower progression (p=0.25) and 8% improved recovery (p=0.33).
RCT 165 low-risk mild COVID-19 patients in Thailand receiving either 180mg/day of Andrographis paniculata extract or placebo for 5 days. No significant difference was found between groups for disease progression, though A. paniculata showed lower progression. Most symptoms improved similarly between groups, though A. paniculata provided faster relief for headaches and loss of smell. All patients recovered with 14 days. The main side effect was mild diarrhea.
Nov 2023, Research in Pharmaceutical Sciences, https://journals.lww.com/10.4103/1735-5362.389947, https://c19p.org/kanokkangsadal

6. Prempree et al., SARS-CoV-2 Clearance from Andrographis paniculata, Boesenbergia rotunda, and Favipiravir among Mild COVID-19 Cases in Klong Prem Central Prison during Mid-2021: a Retrospective Study

60 patient andrographolide late treatment study: 19% improved viral clearance (p=0.61).
Retrospective 120 patients in Thailand, showing improved viral clearance with andrographis compared with favipiravir.
Dec 2022, OSIR, https://www.osirjournal.net/index.php/osir/article/download/311/251, https://c19p.org/prempree

7. Tanwettiyanont et al., Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild coronavirus disease 2019: A retrospective cohort study

605 patient andrographolide late treatment study: 26% higher progression (p=0.4).
Retrospective 605 hospitalized patients in Thailand, showing higher progression with andrographis, without statistical significance.
Aug 2022, Frontiers in Medicine, https://www.frontiersin.org/articles/10.3389/fmed.2022.947373/full, https://c19p.org/tanwettiyanont

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0